Sen. Kohl calls for backup on policing device ads

Share this article:
Sen. Herb Kohl
Sen. Herb Kohl
Sen. Herb Kohl (D-WI) said DTC ads for devices should be regulated just as much as those for drugs and called on his colleague in the House, Rep. Bart Stupak (D-MI), to work with him toward that end.

Kohl chairs the Senate Special Committee on Aging, which recently held hearings on device ads aimed at consumers. Stupak chairs the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations, which has held hearings on DTC advertising for drugs.

“I'm aware that your subcommittee staff has done outstanding work in uncovering deceptive and misleading DTC ads sponsored by the drug industry, which has spent billions of dollars on such marketing efforts during the past decade or so,” Kohl wrote to Stupak on Friday. “We would welcome any further exchange of information with the subcommittee on this important matter, and we stand ready to work with you and your able professional staff in addressing these DTC advertising issues in a cooperative and bicameral manner.”

In the September hearings into device ads, Kohl pronounced himself “prepared to further examine the need for possible moratoriums” on advertising for new devices.

Stupak's office, citing “700 billion distractions,” said today the congressman had not yet replied to Kohl but would do so later this week. Given the two Democrats' shared hostility toward drug industry advertising, it is likely to be affirmative.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...